Literature DB >> 26775358

Total laparoscopic radical hysterectomy: a change in practice for the management of early stage cervical cancer in a U.K. cancer center.

G Angelopoulos, A Etman, D J Cruickshank, J P Twigg.   

Abstract

In order to evaluate the safety, surgical, and oncological outcomes of the introduction of a total laparoscopic radical hysterectomy (TLRH) service, the authors conducted a retrospective review of all TLRHs performed in the present centre from the beginning of the service in August 2010. TLRH appears in this series to be safe. Complication rates were comparable to National Institute for Health and Clinical Excellence (NICE) and literature standards. Oncological outcomes, despite the short follow up period, appear acceptable. TLRH is a valuable alternative to open surgery for the treatment of early cervical cancer.

Entities:  

Mesh:

Year:  2015        PMID: 26775358

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN: 0392-2936            Impact factor:   0.196


  3 in total

1.  A retrospective assessment of the safety and efficacy of laparoscopic radical hysterectomy in Japan during the early years following its introduction: a Japanese Gynecologic Oncology Group study (JGOG1081S).

Authors:  Eiji Kobayashi; Hiroyuki Kanao; Munetaka Takekuma; Shin Nishio; Atsumi Kojima-Chiba; Akiko Tozawa; Satoshi Yamaguchi; Nobuhiro Takeshima; Eiji Nakatani; Mikio Mikami
Journal:  Int J Clin Oncol       Date:  2021-01-12       Impact factor: 3.402

2.  Efficacy of robotic radical hysterectomy for cervical cancer compared with that of open and laparoscopic surgery: A separate meta-analysis of high-quality studies.

Authors:  Sha-Sha Zhang; Tian Ding; Zheng-Hui Cui; Yuan Lv; Ruo-An Jiang
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.817

3.  Comparative analysis of robotic vs laparoscopic radical hysterectomy for cervical cancer.

Authors:  Li Chen; Li-Ping Liu; Na Wen; Xiao Qiao; Yuan-Guang Meng
Journal:  World J Clin Cases       Date:  2019-10-26       Impact factor: 1.337

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.